Latest Conference Articles

The ASRS annual meeting will take place in Stockholm, Sweden on July 16-20, 2024. Several major updates are already anticipated at the event.

The ASRS annual meeting will take place in Stockholm, Sweden on July 16-20, 2024. Several major updates are already anticipated at the event.

The award, supported by Oculis, will recognize outstanding contributions to retina research and will grant €30,000 for research support, and an additional €5,000 directly to the candidate.

Presenters from around the world converge on the Pacific Northwest to highlight innovation.

The 2024 event was held in Seattle, Washington, from May 5 through May 9. Members of the Ophthalmology Times team attended and interviewed several researchers and industry professionals, highlighting news from the meeting.

This podcast features engaging commentary from experts in the clinical management of glaucoma. These experts share information about traditional and newer therapies for glaucoma, including topical drops, sustained drug delivery options, and minimally invasive glaucoma surgery. They discuss safety and efficacy data with an emphasis on appropriate patient selection, as well as key take-home points and practice pearls.

Anat Loewenstein, MD, spoke with Modern Retina about her presentation of AXPAXLI trial results and upcoming trials for this potential treatment, which she gave at Clinical Trials at the Summit meeting held in Park City, Utah on June 8, 2024.

This retrospective real-world evaluation of the drug considered a number of important as-yet-unanswered questions.

To date, only the onset and enlargement of hyperTDs measured using en-face OCT imaging has been validated as a clinical trial endpoint.

ARVO attendees took a deep dive into trends and explored the near future of vision science

Carl Danzig, MD, spoke with us about his presentation on the 24 week results of the PRISM trials for wet AMD. He gave this presentation at Clinical Trials at the Summit meeting in Park City, Utah on June 8, 2024.

Christina Weng, MD, spoke with us about her presentation on the emerging technology of home OCT and its role in AMD. She gave this presentation at Clinical Trials at the Summit meeting being held in Park City, Utah on June 8, 2024.

Michael Singer, MD, spoke with Modern Retina about his presentation of first time data from the CALM Registry at Clinical Trials at the Summit meeting being held in Park City, Utah on June 8, 2024.

Eleonora Lad, MD, PhD, discusses the stages of dry AMD from early to intermediate to geographic atrophy, while also assessing which endpoints are most useful for these different stages.

Arshad M. Khanani, MD, MA, shares what attendees and the retina community can expect from the Clinical Trials at the Summit meeting being held in Park City, Utah on June 8, 2024.

Mark Barakat, MD, sat down with Ophthalmology Times to discuss intraocular pressure outcomes with intravitreal injection of aflibercept, 8mg and 2mg in patients with diabetic macular edema through week 48 of the phase 2/3 PHOTON trial.

Sean Adrean, MD, FAAO, sat down with Ophthalmology Times to discuss a post hoc analysis of the phase 2/3 PHOTON trial and the outcomes of patients with DME and baseline BCVA of 20/50 or worse or 20/40 or better who were treated with aflibercept 8 mg and 2 mg.

Deepak Sambhara, MD, sat down with Ophthalmology Times to discuss the impact of baseline central retinal thickness (CRT) on vision among patients with diabetic macular edema (DME), as a post hoc analysis of the phase 2/3 PHOTON trial.

McDonnell stays focused on helping the next generation of ophthalmologists launch their careers in academics.

Durga Borkar, MD, MMCi, spoke with Modern Retina about the quality data (Qdata) gathered on geographic atrophy as well as the GATHER 1 and GATHER 2 data she presented at the 2024 Retina World Congress meeting in Fort Lauderdale, Florida.

Ash Abbey, MD, spoke with Modern Retina at the 2024 Retina World Congress in Fort Lauderdale, Florida. He shared details about the week 32 data from the phase 2 DAVIO-2 trial for EYP-1901.

J. Fernando Arevalo, MD, PhD, FACS, FASRS, spoke about a recent study looking at what happens to patients with diabetic retinopathy who are lost to follow-up. He presented this research at the 2024 Retina World Congress meeting in Fort Lauderdale, Florida.

David Almeida, MD, PhD, MBA, shared insights on the surgical tools he uses in his practice at the 2024 Retina World Congress meeting in Fort Lauderdale, Florida.

Roy Rubinfeld, MD, MA, discussed EpiSmart cross-linking for keratoconus and the ongoing trials and results at the IKA 2024 Symposium.

At the IKA 2024 Symposium, Michael Belin, MD, discussed the ABCD Progression Display he developed to classify disease severity and help diagnose keratoconus earlier.

Jennifer Harthan, OD, FAAO, FSLS, shared the importance of early diagnostics and pediatric screening of keratoconus at the IKA 2024 Symposium.

Shelley Cutler, OD, FAAO, gives an overview of how keratoconus diagnosis and treatment over the past 40 years has changed and evolved as well as some key insights from the IKA 2024 Symposium.